Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:19 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.
NCT04796324 · Allarity Therapeutics · PHASE2 · terminated · last registry update 2026-03-12 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Company Decision” | – | Registry record, Allarity Therapeutics |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TUBB4B in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-19Phase 3 first posted: CSPC Megalith Biopharmaceutical Co.,Ltd., Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043 + Investigator's Choice of Chemotherapy (paclitaxel，nab paclitaxel，capecitabine，eribulin，carboplatin） (NCT07879911)
- 2026-10-16Also stopped (terminated): Henan Cancer Hospital, Eribulin and Tucidinostat (NCT05335473)
- 2026-10-15Also stopped (terminated): Spanish Breast Cancer Research Group, Trastuzumab + Alpelisib (NCT05063786)
- 2026-07-21Results posted on the registry: University Hospitals Bristol and Weston NHS Foundation Trust, Cabazitaxel + Paclitaxel (NCT03048942)
- 2026-02-04Results posted on the registry: AstraZeneca, Dato-DXd + Capecitabine (NCT05104866)
- 2025-09-15Phase 3 first posted: BioNTech SE, Pumitamig + Nab-paclitaxel/Paclitaxel (NCT07173751)
- 2025-07-28Results posted on the registry: National Cancer Institute (NCI), Copanlisib Hydrochloride + Eribulin Mesylate (NCT04345913)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision